| Literature DB >> 30115985 |
Sandrine Auger1, Céline Henry2, Christine Péchoux3, Sneha Suman4,5, Nathalie Lejal6, Nicolas Bertho6, Thibaut Larcher7, Slavica Stankic4, Jasmina Vidic8,9.
Abstract
The increasing number of multidrug resistant bacteria raises a serious public-health concern, which is exacerbated by the lack of new antibiotics. Metal oxide nanoparticles are already applied as an antibacterial additive in various products used in everyday life but their modes of action have remained unclear. Moreover, their potential negative effects to human health are still under evaluation. We explored effects of mixed metal oxide Zn0.15Mg0.85O on Bacillus subtilis, as a model bacterial organism, and on murine macrophages. Zn0.15Mg0.85O killed planktonic bacterial cells and prevented biofilm formation by causing membrane damages, oxidative stress and metal ions release. When exposed to a sub-inhibitory amount of Zn0.15Mg0.85O, B. subtilis up-regulates proteins involved in metal ions export, oxidative stress response and maintain of redox homeostasis. Moreover, expression profiles of proteins associated with information processing, metabolism, cell envelope and cell division were prominently changed. Multimode of action of Zn0.15Mg0.85O suggests that no single strategy may provide bacterial resistance. Macrophages tolerated Zn0.15Mg0.85O to some extend by both the primary phagocytosis of nanoparticles and the secondary phagocytosis of damaged cells. Bacterial co-treatment with ciprofloxacin and non-toxic amount of Zn0.15Mg0.85O increased antibiotic activity towards B. subtilis and E. coli.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30115985 PMCID: PMC6095908 DOI: 10.1038/s41598-018-30719-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Characterization of Zn0.15Mg0.85O in solutions. (A) DLS measurements showing size distributions of 0.1 mg/mL Zn0.15Mg0.85O in pure water, bacterial LB medium, mammalian cell medium (MEM), in PBS, pH 7.4, and PBS containing 0.05% NP40, 0.05% Tween-20 or 2 mg/mL BSA. All solutions were incubated for 24 h at room temperature before measurements. (B) Zeta–potential analysis of Zn0.15Mg0.85O NPs in different solutions used in this work; (C) O2•− generation of Zn0.15Mg0.85O NPs (0.1 mg/mL, initial concentration) in various solutions, at 25 °C obtained by measuring reduction of 200 µM XTT; (D) No reduction of 200 µM XTT was observed in control experiments without NPs. (E) Generation of O2•− by different concentrations of NPs in PBS; (F) Production of H2O2 by Zn0.15Mg0.85O NPs in PBS and LB obtained by the Amplex red assay.
Figure 2Antibacterial effects of Zn0.15Mg0.85O NPs. (A) Growth curves of B. subtilis in LB medium in the absence (mock) and in the presence of 0.1 mg/mL or 1 mg/mL of Zn0.15Mg0.85O nanoparticles. (B) B. subtilis cell viability obtained upon bacterial cell incubation with 0.1 mg/mL or 1 mg/mL Zn0.15Mg0.85O NPs in LB, as quantified by the colony counting method. (C) TEM cross-section observations of untreated B. subtilis (mock) or treated with 0.1 mg/mL or 0.5 mg/mL Zn0.15Mg0.85O NPs.
Figure 3Comparative proteome analysis of B. subtilis membrane fractions of untreated bacterial cells and cells treated with 0.05 mg/mL Zn0.15Mg0.85O NPs in LB for 1 h. (A) Statistical analysis indicated that 62 proteins had modified abundances in treated and untreated bacteria. Two modes of label free quantification were used: spectral counting (SC) and eXtracted Ion Current ion chromatograms of each peptide (XIC). (B) Representation of the proteome response of B. subtilis to Zn0.15Mg0.85O NPs. The pie chart shows the size of functional categories according to the SubiWiki database. (C) Heatmap presentations of upregulated and downregulated proteins. Left panel, proteins quantified by XIC statistic method; right panel, proteins quantified by SC. Only proteins showing significant abundance change between untreated (mock) and treated bacteria (ANOVA, adjusted p value < 0.05) are displayed.
Proteins up- or down-regulated in B. subtilis cells treated with Zn0.15Mg0.85O.
| Protein name | Fold change ZnMgO vs control | Gene name | Product and Function |
|---|---|---|---|
|
| |||
| CADA | 3.91 |
| Cadmium export, induced by toxic metal ions (Zn(II), Cd(II), Co(II), Ni(II) and Cu(II)) |
| CZCD | 2/0 |
| Cadmium, cobalt and zinc/H(+)-K(+) antiporter |
| CZCO | 6/0 |
| Cation exporter, induced in the presence of toxic metal ions (Zn(II), Cd(II), Co(II)C, Ni(II) and Cu(II)) |
| COPA | 7.61 |
| Copper-exporting P-type ATPase, resistance to copper |
| ZOSA | 1.53 |
| Fe(II) efflux pump, protects the cell against iron intoxication |
|
| |||
| AHPC | 3.51 |
| Alkyl hydroperoxide reductase subunit |
| G20U | 0.28 |
| Mini-ferritin, iron storage protein, resistance against ethanol and paraquat |
| HPF | 3.62 |
| General stress protein, resistance against paraquat |
| MRGA | 0.43 |
| Mini-ferritin, DNA-binding stress protein, iron storage protein |
| SPX | 3/0 |
| Transcriptional regulator of many genes in response to thiol specific oxidative stress |
| YDBP | 3.25 |
| Similar to thioredoxin |
| YDHK | 3/0 |
| General stress protein, survival of ethanol and paraquat stresses |
| YPHP | 9/2 |
| Bacilliredoxin |
| YQIW | 13/3 |
| Bacilliredoxin |
| YRAA | 1.54 |
| General stress protein, degradation of damaged thiol-containing proteins |
|
| |||
| COAX | 2.32 |
| Pantothenate kinase, biosynthesis of coenzyme A |
| DNAK | 1.45 |
| Class I heat-shock protein,molecular chaperone |
| YKVY | 0.56 |
| Degradation of proline-containing peptides |
| RSBW | 1.82 |
| Anti-protein serine kinase, phosphorylates RsbV, control of SigB activity |
| YQCG | 1.43 |
| Toxin, eliminates defective cells from developing biofilms, DNase activity |
| YTXJ | 2.99 |
| Unknown |
Proteins up- or down-regulated in B. subtilis cells treated with Zn0.15Mg0.85O.
| Protein name | Fold change ZnMgO vs control | Gene name | Product and Function |
|---|---|---|---|
|
| |||
| LYTD | 0.62 |
| Peptidoglycan N-acetylglucosaminidase, major autolysin, cell separation |
| PGDS | 1/4 |
| Gamma-DL-glutamyl hydrolase, polyglutamic acid degradation |
| SEPF | 1.58 |
| Part of the divisome, recruits FtsZ to the membrane |
| SP5G | 1.63 |
| RNA-binding regulatory protein, negative effector of asymetric septation at the onset of sporulation |
|
| |||
| ATPE | 2.24 |
| ATP synthase (subunit c) |
| BGLH | 0.45 |
| Phospho-beta-glucosidase, salicin utilization |
| GCSH | 2/0 |
| Glycine cleavage system H protein for lipoic acid biosynthesis |
| KAD | 2.03 |
| Adenylate kinase. ADP formation |
| ODP2 | 1.58 |
| Pyruvate dehydrogenase, links glycolysis and TCA cycle |
| PTV3B | 0.32 |
| Beta-glucoside uptake and phosphorylation, control of LicT activity |
| THIO | 1.72 |
| FAD-dependent glycine oxidase, biosynthesis of thiamine |
| TPIS | 3.33 |
| Triose phosphate isomerase, glycolytic/ gluconeogenic enzyme |
|
| |||
| ABRB | 1.71 |
| Transcriptional regulator of transition state genes |
| PPIB | 4.13 |
| Peptidyl-prolyl cis-trans isomerase (protein folding) |
| PRPC | 1.85 |
| Protein phosphatase (protein modification) |
| RPOZ | 3/0 |
| Omega subunit of RNA polymerase |
| YUKB | 7/2 |
| Membrane FtsK/SpoIIIE-like ATPase |
| CTC | 3.09 |
| Similar to ribosomal protein L25 |
| IF3 | 1.92 |
| Translation initiation factor IF-3 |
| RL6 | 2.08 |
| 50S ribosomal protein L6 |
| RL9 | 1.87 |
| 50S ribosomal protein L9 |
| RL13 | 1.77 |
| 50S ribosomal protein L13 |
| RL18 | 1.58 |
| 50S ribosomal protein L18 |
| RS11 | 3.02 |
| 30S ribosomal protein S11 |
| RS9 | 2.35 |
| 30S ribosomal protein S9 |
| RS12 | 2.00 |
| 30S ribosomal protein S12 |
| RS15 | 3.19 |
| 30S ribosomal protein S15 |
| RS18 | 2.63 |
| 30S ribosomal protein S18 |
| RS19 | 2.95 |
| 30S ribosomal protein S19 |
|
| |||
| YUTI | 2.56 |
| Putative iron-sulfur scaffold protein |
| YTSP | 2.57 |
| Unknown |
| YRPD | 0.46 |
| Unknow |
| YUAE | 1.7 |
| Unknown |
| YCNE | 2.11 |
| Unknown |
| YXKC | 0.64 |
| Unknown |
| YTKA | 1.49 |
| Unknown |
| YJHA | 1.61 |
| Unknown |
| YSDC | 0.49 |
| Similar to endo-1.4-beta-glucanase |
| YTOP | 0.58 |
| Similar to glutamyl aminopeptidase |
| YERC | 1.73 |
| Unknown |
| YNCM | 0.65 |
| Unknown |
Figure 4Effect of Zn0.15Mg0.85O NPs on biofilm formation by NDmed B. subtilis in LB and MSgg medium (A,B). Bacterial cells of were incubated in the absence of NPs and in the presence of 0.1 mg/mL Zn0.15Mg0.85O. Microtiter plates were stained with crystal violet after incubation at 30 °C without agitation for 24 h. Quantification of biofilm density was obtained by measuring OD at 595 nm of solubilized crystal violet formed in microtiter plate assay. The error bars represent mean ± SD from at least four independent experiments. (C) Pellicle biofilm formation by NDmed strain in MSgg medium alone and with added Zn0.15Mg0.85O NPs at 0.1 mg/mL and 0.5 mg/mL.
Figure 5Cytotoxic effect of Zn0.15Mg0.85O NPs on macrophage cells. (A) MTT reduction in macrophages incubated with Zn0.15Mg0.85O NPs at various concentrations overnight. The % of MTT reduction relative to that of control cells incubated with PBS is plotted. The error bars represent SD of the means over total of 8 replicates, ** correspond to P-value < 0.01, and ***P < 0.001. (B) Viability of macrophages incubated with 0.1 mg/mL or 1 mg/mL Zn0.15Mg0.85O NPs overnight was estimated by acridine orange staining and flow cytometry analysis. Note that there was no significant difference in acridine orange fluorescence between untreated (mock) and cells treated with 0.1 mg/mL Zn0.15Mg0.85O. (C) Representative thin section electron micrographs of untreated macrophage cells and (D) macrophages cells incubated with 0.1 mg/mL Zn0.15Mg0.85O for 24 h. m, mitochondria; er, endoplasmic reticulum; Lys, lysosome; S-m, swelling mitochondria.
Figure 6Zn0.15Mg0.85O potentiates antibiotic activity of ciprofloxacin against B. subtilis and E. coli. Paper disk diffusion assay was performed on BHI agar plates with disks loaded with 5 µg ciprofloxacin alone or co-loaded with various amount of Zn0.15Mg0.85O NPs. Disks loaded only with corresponding amounts of Zn0.15Mg0.85O NPs were tested as controls. Left panel illustrates the distribution of disks per plate and two scanned plates showing the effect of Zn0.15Mg0.85O NPs on the activity of ciprofloxacin. For both strains tested, the inhibition zone around disc co-loaded with Zn0.15Mg0.85O and ciprofloxacin was broader than that around disk loaded only with ciprofloxacin. Bars indicates the percent increase in zone of inhibition for ciprofloxacin with NPs relative to that of ciprofloxacin alone. Error bars are 95% confidence intervals.